Making the Call in Relapsed or Refractory Multiple Myeloma
Incorporating Bispecific Antibody Therapy Into Practice
Diagnosis and management of multiple myeloma: a review.
Cowan AJ, et al. JAMA. 2022;327(5):464-477.
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.
Rajkumar SV. Am J Hematol. 2022;97(8):1086-1107.
Targeting BCMA in multiple myeloma.
Tan CR, Shah UA. Curr Hematol Malig Rep. 2021;16(5):367-383.
The emerging therapeutic landscape of relapsed/refractory multiple myeloma.
Tanenbaum B, et al. Ann Hematol. 2023;102(1):1-11.
Palumbo A, et al. J Clin Oncol. 2015;33(26):2863-2869.
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.
Morris EC, et al. Nat Rev Immunol. 2022;22(2):85-96.
Ludwig H, et al. Lancet Oncol. 2023;24(6):e255-e269.
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Lesokhin AM, et al. Nat Med. 2023;29(9):2259-2267.
Teclistamab in relapsed or refractory multiple myeloma.
Moreau P, et al. N Engl J Med. 2022;387(6):495-505.
Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma.
Chari A, et al. N Engl J Med. 2022;387(24):2232-2244.
Guidelines
Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology.
Kumar SK, et al. J Natl Compr Canc Netw. 2023;21(12):1281-1301.
Clinician Resources
When and How to Choose Bispecific Antibody Therapy in Relapsed or Refractory Multiple Myeloma
A Phone-a-Friend™ Series - Module 1
| Faculty: | Joseph Mikhael, MD, MEd, FRCPC, FACP; Caitlin Costello, MD |
| Release: | 05/24/2024 |
| Expiration: | 05/24/2025 |
Getting Started: Incorporating Bispecifics Into Clinical Practice
A Phone-a-Friend™ Series - Module 2
| Faculty: | Caitlin Costello, MD; Joseph Mikhael, MD, MEd, FRCPC, FACP |
| Release: | 06/04/2024 |
| Expiration: | 06/04/2025 |
